Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrew Alan Nierenberg, M.D.

Co-Author

This page shows the publications co-authored by Andrew Nierenberg and Roy Perlis.
Connection Strength

3.301
  1. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med. 2008 Apr; 50(4):428-36.
    View in: PubMed
    Score: 0.388
  2. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry. 2006 Feb; 163(2):225-31.
    View in: PubMed
    Score: 0.334
  3. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry. 2005 Oct; 162(10):1957-60.
    View in: PubMed
    Score: 0.326
  4. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013 Jul; 74(7):e636-41.
    View in: PubMed
    Score: 0.140
  5. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. J Clin Psychopharmacol. 2013 Jun; 33(3):343-50.
    View in: PubMed
    Score: 0.139
  6. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust N Z J Psychiatry. 2013 Jan; 47(1):26-42.
    View in: PubMed
    Score: 0.130
  7. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol. 2012 Aug; 26(8):1108-12.
    View in: PubMed
    Score: 0.124
  8. A critical review of pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol. 2011 Nov; 14(10):1417-31.
    View in: PubMed
    Score: 0.119
  9. Assuring that double-blind is blind. Am J Psychiatry. 2010 Mar; 167(3):250-2.
    View in: PubMed
    Score: 0.111
  10. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry. 2010 Mar; 71(3):296-303.
    View in: PubMed
    Score: 0.111
  11. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. J Clin Psychiatry. 2010 Feb; 71(2):194-200.
    View in: PubMed
    Score: 0.110
  12. Stability of symptoms across major depressive episodes in bipolar disorder. Bipolar Disord. 2009 Dec; 11(8):867-75.
    View in: PubMed
    Score: 0.109
  13. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord. 2009 Jun; 11(4):391-400.
    View in: PubMed
    Score: 0.105
  14. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006 Feb; 163(2):217-24.
    View in: PubMed
    Score: 0.084
  15. The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry. J Clin Psychiatry. 2006; 67 Suppl 11:3-7.
    View in: PubMed
    Score: 0.083
  16. Revisiting depressive-prone bipolar disorder: polarity of initial mood episode and disease course among bipolar I systematic treatment enhancement program for bipolar disorder participants. Biol Psychiatry. 2005 Oct 01; 58(7):549-53.
    View in: PubMed
    Score: 0.082
  17. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2004 May 01; 55(9):875-81.
    View in: PubMed
    Score: 0.074
  18. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 2004 May-Jun; 45(3):224-9.
    View in: PubMed
    Score: 0.074
  19. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J Affect Disord. 2004 Apr; 79(1-3):291-5.
    View in: PubMed
    Score: 0.074
  20. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand. 2003 Dec; 108(6):432-8.
    View in: PubMed
    Score: 0.072
  21. Bipolar depression: relationship between episode length and antidepressant treatment. Psychol Med. 2002 Nov; 32(8):1417-23.
    View in: PubMed
    Score: 0.067
  22. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol. 2002 Oct; 22(5):474-80.
    View in: PubMed
    Score: 0.066
  23. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 2002 Mar-Apr; 10(2):109-14.
    View in: PubMed
    Score: 0.064
  24. A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder. Am J Addict. 2016 Mar; 25(2):94-8.
    View in: PubMed
    Score: 0.042
  25. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013 Nov; 170(11):1249-62.
    View in: PubMed
    Score: 0.036
  26. Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD). CNS Neurosci Ther. 2012 Mar; 18(3):243-9.
    View in: PubMed
    Score: 0.030
  27. Personality and bipolar disorder: dissecting state and trait associations between mood and personality. Psychol Med. 2011 Aug; 41(8):1593-604.
    View in: PubMed
    Score: 0.029
  28. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2010 Mar; 167(3):289-97.
    View in: PubMed
    Score: 0.027
  29. Cigarette smoking is associated with suicidality in bipolar disorder. Bipolar Disord. 2009 Nov; 11(7):766-71.
    View in: PubMed
    Score: 0.027
  30. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009 Feb; 166(2):173-81.
    View in: PubMed
    Score: 0.026
  31. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry. 2006 Dec; 67(12):1907-11.
    View in: PubMed
    Score: 0.022
  32. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry. 2006 Feb; 188:180-5.
    View in: PubMed
    Score: 0.021
  33. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Aug; 66(8):1038-42.
    View in: PubMed
    Score: 0.020
  34. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics. 2004 Sep-Oct; 45(5):419-25.
    View in: PubMed
    Score: 0.019
  35. Presence of irritability during depressive episodes in bipolar disorder. CNS Spectr. 2004 Mar; 9(3):227-31.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.